Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05572476
Title Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer (LURBIMUNE)
Acronym LURBIMUNE
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Institut Bergonie
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA


No variant requirements are available.